NVCR

16.49

2.89% -0.49

Dopo l'orario di chiusura: 16.51 0.02 +0.12%

Novocure Ltd (NVCR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché NVCR Giù? Forum Previsione

Precedente Chiudi:

$16.98

Aprire:

$16.25

Volume 24 ore:

985.36K

Relative Volume:

1.14

Capitalizzazione di mercato:

$1.78B

Reddito:

$577.74M

Utile/perdita netta:

$-149.78M

Rapporto P/E:

-11.78

EPS:

-1.4

Flusso di cassa netto:

$-78.21M

1 W Prestazione:

-12.57%

1M Prestazione:

-9.35%

6M Prestazione:

+12.02%

1 anno Prestazione:

+15.40%

Intervallo 1D:

$15.92

$16.80

Intervallo di 1 settimana:

$15.92

$18.58

Portata 52W:

$11.70

$34.13

Novocure Ltd Stock (NVCR) Company Profile

Nome

Novocure Ltd

Settore

Healthcare (1162)

Industria

Medical Devices (157)

Telefono

44 (0)15 3475 6700

Indirizzo

NO. 4 THE FORUM, ST. HELIER

Dipendente

1,453

Cinguettio

@novocure

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

NVCR's Discussions on Twitter

Confronta NVCR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NVCR Novocure Ltd	16.49	1.78B	577.74M	-149.78M	-78.21M	-1.40
ABT Abbott Laboratories	124.44	215.82B	41.95B	13.40B	6.35B	7.65
SYK Stryker Corp	345.80	142.48B	22.60B	2.99B	3.49B	7.76
BSX Boston Scientific Corp	89.70	132.67B	16.75B	1.85B	2.37B	1.25
MDT Medtronic Plc	82.88	106.28B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	69.36	40.63B	5.72B	4.17B	259.90M	6.97

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-02	Aggiornamento	Evercore ISI	In-line → Outperform
2024-10-16	Aggiornamento	H.C. Wainwright	Neutral → Buy
2023-11-20	Ripresa	JP Morgan	Neutral
2023-08-28	Downgrade	H.C. Wainwright	Buy → Neutral
2023-08-08	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-08-04	Iniziato	SVB Securities	Outperform
2023-07-31	Aggiornamento	Evercore ISI	Underperform → In-line
2023-06-07	Aggiornamento	Wedbush	Underperform → Neutral
2023-05-16	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-17	Downgrade	JP Morgan	Neutral → Underweight
2023-01-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-01-05	Reiterato	H.C. Wainwright	Buy
2022-11-29	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-10-24	Downgrade	Piper Sandler	Overweight → Neutral
2022-07-05	Downgrade	Evercore ISI	In-line → Underperform
2022-05-16	Iniziato	H.C. Wainwright	Buy
2022-02-08	Iniziato	Loop Capital	Buy
2022-02-02	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-20	Aggiornamento	Truist	Hold → Buy
2022-01-03	Aggiornamento	Evercore ISI	Underperform → In-line
2021-07-01	Downgrade	Mizuho	Buy → Neutral
2021-04-14	Downgrade	Wedbush	Neutral → Underperform
2021-01-25	Reiterato	Piper Sandler	Overweight
2020-09-23	Iniziato	Northland Capital	Outperform
2020-09-18	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-09-17	Downgrade	Truist	Buy → Hold
2020-06-01	Ripresa	Oppenheimer	Perform
2020-05-01	Downgrade	Oppenheimer	Outperform → Perform
2020-04-09	Downgrade	Evercore ISI	In-line → Underperform
2020-03-05	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-01-02	Downgrade	Evercore ISI	Outperform → In-line
2019-07-29	Aggiornamento	SunTrust	Hold → Buy
2019-07-26	Downgrade	JP Morgan	Overweight → Neutral
2019-07-26	Downgrade	Wedbush	Outperform → Neutral
2019-03-20	Iniziato	SunTrust	Hold
2018-11-02	Downgrade	Wells Fargo	Outperform → Market Perform
2018-07-16	Iniziato	Evercore ISI	Outperform
2018-04-18	Reiterato	Mizuho	Buy
2018-02-23	Reiterato	Mizuho	Buy
2017-05-24	Aggiornamento	Wells Fargo	Market Perform → Outperform
2016-07-29	Reiterato	Wedbush	Outperform
2016-01-19	Iniziato	Barclays	Underweight
2015-12-02	Iniziato	Deutsche Bank	Hold

Mostra tutto

Novocure Ltd Borsa (NVCR) Ultime notizie

Apr 03, 2025

Thrivent Financial for Lutherans Reduces Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Apr 03, 2025

Corebridge Financial Inc. Has $1.58 Million Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World

Apr 03, 2025

Apr 01, 2025

Novocure to Report First Quarter 2025 Financial Results - Yahoo Finance

Apr 01, 2025

Mar 27, 2025

Emerald Advisers LLC Takes Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Mar 27, 2025

Mar 22, 2025

Proficio Capital Partners LLC Acquires Shares of 30,158 NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 22, 2025

Mar 21, 2025

NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from Analysts - The AM Reporter

Mar 21, 2025

Mar 19, 2025

NovoCure Beats Investor Lawsuit Over Cancer Trial Data Results - Bloomberg Law News

Mar 19, 2025

Charles Schwab Investment Management Inc. Has $24.92 Million Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 19, 2025

NovoCure Beats Investor Suit Over Cancer Therapy Trial Data (1) - Bloomberg Law News

Mar 19, 2025

NovoCure (NASDAQ:NVCR) Rating Increased to Hold at StockNews.com - Defense World

Mar 19, 2025

Mar 15, 2025

Bank of New York Mellon Corp Increases Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 15, 2025

Mar 12, 2025

An Analysis of NovoCure Ltd (NVCR)’s Potential Price Growth - Knox Daily

Mar 12, 2025

Mar 11, 2025

Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields - Investing.com India

Mar 11, 2025

Novocure at Leerink’s Global Healthcare Conference: Expanding TTFields By Investing.com - Investing.com UK

Mar 11, 2025

Mar 08, 2025

Principal Financial Group Inc. Invests $272,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 08, 2025

Mar 07, 2025

Novocure Ltd. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 06, 2025

Truist Financial Corp Invests $340,000 in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 06, 2025

Don't Ignore The Insider Selling In NovoCure - Simply Wall St

Mar 06, 2025

Mar 05, 2025

Novocure’s EVP sells shares worth $46,841 By Investing.com - Investing.com Australia

Mar 05, 2025

Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR) - GuruFocus.com

Mar 05, 2025

Mar 04, 2025

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - MSN

Mar 04, 2025

Novocure’s chief innovation officer sells shares worth $5,071 - Investing.com India

Mar 04, 2025

Novocure’s EVP sells shares worth $46,841 - Investing.com India

Mar 04, 2025

Novocure CEO Ashley Cordova sells shares valued at $38,055 By Investing.com - Investing.com South Africa

Mar 04, 2025

Novocure CEO Ashley Cordova sells shares valued at $38,055 - Investing.com

Mar 04, 2025

Novocure COO sells shares worth $4,634 By Investing.com - Investing.com Australia

Mar 04, 2025

Novocure COO sells shares worth $4,634 - Investing.com

Mar 04, 2025

Novocure’s COO Paravasthu Mukund sells shares worth $39,687 By Investing.com - Investing.com Australia

Mar 04, 2025

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference - Yahoo Finance

Mar 04, 2025

NovoCure (NASDAQ:NVCR) Lowered to “Sell” Rating by StockNews.com - Defense World

Mar 04, 2025

Mar 03, 2025

Novocure executive sells shares for $296,256 By Investing.com - Investing.com South Africa

Mar 03, 2025

Novocure’s COO Paravasthu Mukund sells shares worth $39,687 - Investing.com India

Mar 03, 2025

Novocure CEO Ashley Cordova disposes shares worth $266,126 - Investing.com India

Mar 03, 2025

Novocure CEO Ashley Cordova disposes shares worth $266,126 By Investing.com - Investing.com Canada

Mar 03, 2025

Q1 Earnings Estimate for NovoCure Issued By Leerink Partnrs - Defense World

Mar 03, 2025

Mar 02, 2025

New York State Common Retirement Fund Increases Holdings in NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 02, 2025

New York State Common Retirement Fund Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Armenian Reporter

Mar 02, 2025

Mar 01, 2025

Some Confidence Is Lacking In NovoCure Limited (NASDAQ:NVCR) As Shares Slide 25% - Simply Wall St

Mar 01, 2025

Los Angeles Capital Management LLC Acquires 55,334 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Mar 01, 2025

Rhumbline Advisers Buys 3,115 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

Mar 01, 2025

Feb 28, 2025

NovoCure (NASDAQ:NVCR) Posts Earnings Results, Misses Expectations By $0.27 EPS - MarketBeat

Feb 28, 2025

Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025

Commit To Buy NovoCure At $13, Earn 22.3% Using Options - Nasdaq

Feb 28, 2025

NovoCure (NASDAQ:NVCR) Shares Gap Down After Earnings Miss - MarketBeat

Feb 28, 2025

NovoCure Full Year 2024 Earnings: EPS Misses Expectations - Simply Wall St

Feb 28, 2025